Authors: Wako Ryszard¹; Bolko Pawe²; Owecki Maciej²; Jaskua Magdalena²; Sowiski Jerzy²

Source: Pharmacy World and Science, Volume 26, Number 6, December 2004 , pp. 324-327(4)

Publisher: Springer

Abstract:

Objective: The efficacy of somatostatin analogues in the treatment of acromegaly is not always equal and therefore we wanted to evaluate the efficacy of therapy with octreotide long acting release (LAR) in patients with monohormonal tumours (somatotropinomas) in comparison to individuals with mixed pituitary tumours secreting alphasubunit.

Method: The 35 acromegalic patients (18 males and 17 females), aged 41.8 ± 8.8 years, were divided into 2 groups according to the secreted hormones: 1 with mixed pituitary tumours with elevated growth hormone and alpha-subunit concentrations, the other with isolated growth hormone hypersecretion and normal alpha-subunit levels. The groups included 19 patients (9 males and 10 females), aged 40.1 ± 7.1 years (mean ± SD), and 16 patients (9 males and 7 females) aged 43.8 ± 8.8 years (mean ± SD), respectively.

Results: The decrease of GH and IGF-I levels after octreotide LAR treatment were observed in both groups. However, the reduction of GH and IGF-I concentrations was not equal in both groups and the differences between both groups were statistically significant (P=0.01 for GH levels, and P=0.047 for IGF-I levels).

Conclusions: After octreotide LAR treatment, the decrease of GH level and of mean IGF-I values was greater in patients with mixed pituitary tumours and high alpha-subunit concentrations than in patients with isolated GH hypersecretion and normal alpha-subunit levels.

Keywords: Acromegaly; Alpha subunit; Octreotide; Pharmacotherapy; Pituitary tumours; Somatostatin analogues

Document Type: Research article

DOI: http://dx.doi.org/10.1007/s11096-004-9010-y

Affiliations: 1: Department of Endocrinology, Metabolism and Internal Medicine, 011011011011011011011011Pozna University of Medical Sciences, ul. Przybyszewskiego 49, 01101101101101101101101101160-355 Pozna, 011011011011011011011011011Poland, Email: rwasko@amp.edu.pl University of Medical Sciences, ul. Przybyszewskiego 49, 01101101101101101101101101160-355 Pozna, 011011011011011011011011011Poland, Email: rwasko@amp.edu.pl "> 2: Department of Endocrinology, Metabolism and Internal Medicine, 011011011011011011011011Pozna University of Medical Sciences, ul. Przybyszewskiego 49, 01101101101101101101101101160-355 Pozna, 011011011011011011011011011Poland, University of Medical Sciences, ul. Przybyszewskiego 49, 01101101101101101101101101160-355 Pozna, 011011011011011011011011011Poland,">

Publication date: 2004-12-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Wako Ryszard ;  Bolko Pawe ;  Owecki Maciej ;  Jaskua Magdalena ;  Sowiski Jerzy

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers